Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
2
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedJapanese GAAPNet Sales1,989¥ millionYear on year +2.0%Progress 32.0%
Operating profit803¥ millionYear on year -2.4%Progress 43.9%
Ordinary income825¥ millionYear on year -1.9%Progress 43.7%
Net income attributable to owners of the parent563¥ millionYear on year -2.6%Progress 43.2%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥23.07
Financial position at period-end
Total assets6,956¥ million
of which net assets 5,678 ¥ millionEquity ratio 81.1%vs. prior year-end +1.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueHealthcare business ¥1,822,281 thousand (YoY +4.6%), Public-sector business ¥103,038 thousand (YoY -45.7%), Healthtech business ¥64,568 thousand (YoY +224.5%)
Segment profitHealthcare business ¥778,240 thousand (YoY +5.2%), Public-sector business ¥32,021 thousand (YoY -75.9%), Healthtech business ¥-6,559 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥6,209 million (YoY +1.6%)
Operating profit¥1,829 million (YoY +2.2%)
Ordinary income¥1,889 million (YoY +2.6%)
Net income¥1,302 million (YoY +3.6%)
Revision to Earnings ForecastNo revision
Annual Dividend Forecast¥22 → ¥27
Factors Behind Changes in Business Performance
Revenue increased as sales in the Healthcare business remained solid and revenue from the Medical Data Platform business was recognized. Personnel expenses increased due to strategic hiring, and each profit figure fell below the year-earlier period. The Public-sector business reported lower revenue and profit due to the反動 from the contribution of a large project to revenue in the year-earlier period.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Excluded 0 / Name of newly added company Not disclosed / Excluded Company Name Not disclosed
Breakdown of extraordinary income (loss)No applicable matters
Depreciation and amortization¥8,896 thousand
Orders received and order backlogOrders received ¥1,152,982 thousand / Order backlog ¥1,569,420 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNone (対象者：Not disclosed)
Issued Shares at Period-End26,608,800 Shares
Treasury Shares at Period-End2,199,665 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥1,989 million (YoY +2.0%) |
| Operating profit | ¥803 million (YoY -2.4%) |
| Ordinary income | ¥825 million (YoY -1.9%) |
| Profit attributable to owners of the parent | ¥563 million (YoY -2.6%) |
| Net income per share | ¥23.07 |
| Equity ratio | End of the current fiscal period 81.1 / End of previous period 79.9 |
| Total assets | ¥6,956 million |
| Net assets | ¥5,678 million |
| Full-year earnings forecast | Net Sales ¥6,209 million (YoY +1.6%) / Operating profit ¥1,829 million (YoY +2.2%) / Ordinary income ¥1,889 million (YoY +2.6%) / Net income ¥1,302 million (YoY +3.6%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥22 → ¥27 |
| Segment revenue | Healthcare business ¥1,822,281 thousand (YoY +4.6%), Public-sector business ¥103,038 thousand (YoY -45.7%), Healthtech business ¥64,568 thousand (YoY +224.5%) |
| Segment profit | Healthcare business ¥778,240 thousand (YoY +5.2%), Public-sector business ¥32,021 thousand (YoY -75.9%), Healthtech business ¥-6,559 thousand |
| Orders received and order backlog | Orders received ¥1,152,982 thousand / Order backlog ¥1,569,420 thousand |
| Depreciation and amortization | ¥8,896 thousand |
| Breakdown of extraordinary income (loss) | No applicable matters |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Name of newly added company Not disclosed / Excluded Company Name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 26,608,800 Shares |
| Treasury Shares at Period-End | 2,199,665 Shares |
| Factors Behind Changes in Business Performance | Revenue increased as sales in the Healthcare business remained solid and revenue from the Medical Data Platform business was recognized. Personnel expenses increased due to strategic hiring, and each profit figure fell below the year-earlier period. The Public-sector business reported lower revenue and profit due to the反動 from the contribution of a large project to revenue in the year-earlier period. |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased as sales in the Healthcare business remained solid and revenue from the Medical Data Platform business was recognized in the Healthtech business. On the profit side, personnel expenses increased due to strategic hiring to strengthen organic growth.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.